Skip to content

Study · Non-randomized trial · n = 10 · 2018

7 results

Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.

Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Sberna AL, Petit JM, Degrace P, Demizieux L

Arteriosclerosis, thrombosis, and vascular biology1 Sept 2018Cited by 60 (Europe PMC)

PMID30026275 (opens in a new tab)DOI10.1161/atvbaha.118.310990 (opens in a new tab)PepBankPUB-30026275
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, 6 months of liraglutide reduced the ApoB48 pool compared with before treatment.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered the amount of ApoB48, a fat-carrying particle protein, compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseApoB48 pool size
    Study

    n = 10

    Comparator
    Baseline before liraglutide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.2 mg/d · 6 monthsAs given in this study (human).

    Measurements

    ApoB48 pool
    65 mg
    after liraglutide
    ApoB48 pool
    162 mg
    before treatment

    Source sentences

    Summary
    In diabetic patients, liraglutide treatment induced a dramatic reduction of ApoB48 pool (65±38 versus 162±87 mg; P=0.005) because of a significant decrease in ApoB48 production rate (3.02±1.33 versus 6.14±4.27 mg kg-1 d-1; P=0.009) and a significant increase in ApoB48 fractiona…
    1 context sentence
    Summary · context
    Approach and Results- We performed an in vivo kinetic study with stable isotopes (D8-valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d).
  2. 02HumanNon-randomized trialMechanism

    In adults with type 2 diabetes, 6 months of liraglutide reduced the ApoB48 production rate compared with before treatment.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered how fast the body makes ApoB48 compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseApoB48 production rate
    Study

    n = 10

    Comparator
    Baseline before liraglutide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.2 mg/d · 6 monthsAs given in this study (human).

    Measurements

    ApoB48 production rate
    3.02 mg/kg/d
    after liraglutide
    ApoB48 production rate
    6.14 mg/kg/d
    before treatment

    Source sentences

    Summary
    In diabetic patients, liraglutide treatment induced a dramatic reduction of ApoB48 pool (65±38 versus 162±87 mg; P=0.005) because of a significant decrease in ApoB48 production rate (3.02±1.33 versus 6.14±4.27 mg kg-1 d-1; P=0.009) and a significant increase in ApoB48 fractiona…
    1 context sentence
    Summary · context
    Approach and Results- We performed an in vivo kinetic study with stable isotopes (D8-valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d).
  3. 03HumanNon-randomized trialMechanism

    In adults with type 2 diabetes, 6 months of liraglutide increased the ApoB48 fractional catabolic rate compared with before treatment.

    In plain wordsIn adults with type 2 diabetes, liraglutide sped up the breakdown of ApoB48 compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseApoB48 fractional catabolic rate
    Study

    n = 10

    Comparator
    Baseline before liraglutide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.2 mg/d · 6 monthsAs given in this study (human).

    Measurements

    ApoB48 fractional catabolic rate
    5.12 pool/d
    after liraglutide
    ApoB48 fractional catabolic rate
    3.69 pool/d
    before treatment

    Source sentences

    Summary
    In diabetic patients, liraglutide treatment induced a dramatic reduction of ApoB48 pool (65±38 versus 162±87 mg; P=0.005) because of a significant decrease in ApoB48 production rate (3.02±1.33 versus 6.14±4.27 mg kg-1 d-1; P=0.009) and a significant increase in ApoB48 fractiona…
    1 context sentence
    Summary · context
    Approach and Results- We performed an in vivo kinetic study with stable isotopes (D8-valine) in the fed state in 10 patients with type 2 diabetes mellitus before treatment and 6 months after the initiation of treatment with liraglutide (1.2 mg/d).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, 1 week of liraglutide significantly reduced plasma triglycerides after a fat load.

    In plain wordsIn mice, one week of liraglutide lowered blood triglycerides after a fat load.

    Peptide
    Liraglutide
    Outcome
    DecreasePostload plasma triglycerides
    Study

    mousen: not reported in source

    Mice treated with liraglutide for 1 week
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 1 weekAs given in this study (mouse).

    Source sentences

    Summary
    One-week treatment with liraglutide significantly reduced postload plasma triglycerides in mice
    1 context sentence
    Summary · context
    We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides and analysed in vitro on jejunum, the direct effect of liraglutide on the expression of genes involved in the biosynthesis of chylomicron.
  5. 05LabEx vivo tissueMechanism

    In jejunum tissue studied in vitro, liraglutide reduced expression of the ApoB48 gene.

    In plain wordsIn lab tests on gut tissue, liraglutide lowered activity of the gene for ApoB48.

    Peptide
    Liraglutide
    Outcome
    DecreaseApoB48 gene expression
    Study

    n: not reported in source

    Jejunum tissue analysed in vitro
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One-week treatment with liraglutide significantly reduced postload plasma triglycerides in mice and liraglutide, in vitro, reduced the expression of ApoB48, DGAT1 (diacylglycerol O-acyltransferase 1), and MTP (microsomal transfer protein) genes.
    1 context sentence
    Summary · context
    We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides and analysed in vitro on jejunum, the direct effect of liraglutide on the expression of genes involved in the biosynthesis of chylomicron.
  6. 06LabEx vivo tissueMechanism

    In jejunum tissue studied in vitro, liraglutide reduced expression of the DGAT1 gene.

    In plain wordsIn lab tests on gut tissue, liraglutide lowered activity of the DGAT1 gene.

    Peptide
    Liraglutide
    Outcome
    DecreaseDGAT1 gene expression
    Study

    n: not reported in source

    Jejunum tissue analysed in vitro
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One-week treatment with liraglutide significantly reduced postload plasma triglycerides in mice and liraglutide, in vitro, reduced the expression of ApoB48, DGAT1 (diacylglycerol O-acyltransferase 1), and MTP (microsomal transfer protein) genes.
    1 context sentence
    Summary · context
    We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides and analysed in vitro on jejunum, the direct effect of liraglutide on the expression of genes involved in the biosynthesis of chylomicron.
  7. 07LabEx vivo tissueMechanism

    In jejunum tissue studied in vitro, liraglutide reduced expression of the MTP gene.

    In plain wordsIn lab tests on gut tissue, liraglutide lowered activity of the MTP gene.

    Peptide
    Liraglutide
    Outcome
    DecreaseMTP gene expression
    Study

    n: not reported in source

    Jejunum tissue analysed in vitro
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One-week treatment with liraglutide significantly reduced postload plasma triglycerides in mice and liraglutide, in vitro, reduced the expression of ApoB48, DGAT1 (diacylglycerol O-acyltransferase 1), and MTP (microsomal transfer protein) genes.
    1 context sentence
    Summary · context
    We also evaluated, in mice, the effect of a 1-week liraglutide treatment on postload triglycerides and analysed in vitro on jejunum, the direct effect of liraglutide on the expression of genes involved in the biosynthesis of chylomicron.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 4NCT02721888

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Centre Hospitalier Universitaire Dijonn = 12710 Jul 2012 to 2 Oct 2019 (primary)

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 6 Feb 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.